SOPHiA GENETICS SA (SOPH)
NASDAQ: SOPH · Real-Time Price · USD
3.610
+0.170 (4.94%)
At close: Aug 22, 2025, 4:00 PM
3.580
-0.030 (-0.83%)
After-hours: Aug 22, 2025, 7:18 PM EDT
Company Description
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
SOPHiA GENETICS SA
| Country | Switzerland |
| Founded | 2011 |
| IPO Date | Jul 23, 2021 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 423 |
| CEO | Jurgi Camblong |
Contact Details
Address: La Pièce 12 Rolle, 1180 Switzerland | |
| Phone | 41 21 694 10 60 |
| Website | sophiagenetics.com |
Stock Details
| Ticker Symbol | SOPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001840706 |
| CUSIP Number | H82027105 |
| ISIN Number | CH1125843347 |
| SIC Code | 7374 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jurgi Camblong M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Ross Jordan Muken B.Sc. | President |
| George A. Cardoza M.B.A. | Executive Vice President and Chief Financial Officer |
| Abhimanyu Verma | Senior Vice President and Chief Technology Officer |
| Dr. Zhenyu Xu Ph.D. | Executive Vice President and Chief Scientific Officer |
| Kellen Sanger | Head of Strategy and Investor Relations |
| Daan van Well L.L.M., M.B.A. | Executive Vice President, Chief Legal and Regulatory Officer |
| Manuela Da Silva Valente B.A. | Executive Vice President and Chief People Officer |
| Kevin Puylaert | Vice President and MD of EMEA |
| Dr. Philippe Menu M.B.A., M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2025 | 144 | Filing |
| Aug 19, 2025 | 144 | Filing |
| Aug 15, 2025 | EFFECT | Notice of Effectiveness |
| Aug 15, 2025 | EFFECT | Notice of Effectiveness |
| Aug 15, 2025 | 424B5 | Filing |
| Aug 15, 2025 | 424B3 | Prospectus |
| Aug 5, 2025 | F-3 | Filing |
| Aug 5, 2025 | F-3 | Filing |
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Jul 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |